After-surgery targeted pill to prevent relapse in EGFR lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies whether an EGFR-targeted pill, given after surgery, can reduce the chance of lung cancer coming back. It specifically looks at people whose tumors have certain EGFR changes and where “minimal residual disease” (tiny leftover cancer) is being used to guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to under 80 years old, and provide written consent
- Have had complete surgery for stage IB to IIIB non-small-cell lung cancer (NSCLC) with no cancer left at the margins (R0 resection)
- Your tumor must have specific EGFR mutations (exon 19 deletion, L858R in exon 21, or L861Q, or G719X)
- Be well enough for treatment (doctor rates you as ECOG 0–1) and expect to live at least 12 weeks
- Have blood, liver, and kidney lab results high enough for medication safety
- Women must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
This trial tests whether taking aumolertinib (a pill that targets specific EGFR mutations) after lung cancer surgery helps prevent the cancer from coming back. It is for people with early-stage non-small cell lung cancer that has an EGFR mutation and has been completely removed.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
Hear when a new MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.